Veracyte VCYT Business Segments — Other research and development expenses
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Veracyte in its filing.
Tagged under the XBRL concept us-gaap:OtherResearchAndDevelopmentExpense.
The official record: Veracyte’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Veracyte's business segments — other research and development expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Veracyte's business segments — other research and development expenses?
- Veracyte (VCYT) reported business segments — other research and development expenses of $5.46M in Q1 2026.
- How has Veracyte's business segments — other research and development expenses changed year-over-year?
- Veracyte's business segments — other research and development expenses increased by 200.8% year-over-year, from $1.82M to $5.46M.
- What is the long-term trend for Veracyte's business segments — other research and development expenses?
- Over 3 years (2022 to 2025), Veracyte's business segments — other research and development expenses has grown at a 22.1% compound annual growth rate (CAGR), from $4.67M to $8.5M.
- What does business segments — other research and development expenses mean?
- Includes miscellaneous research and development costs for the segment that fall outside of primary direct R&D activities. These expenses typically cover supporting infrastructure, administrative R&D overhead, or secondary innovation projects.